Literature DB >> 11106361

A clinical assessment of neurofibromatosis type 1 (NF1) and segmental NF in Northern Finland.

M Poyhonen.   

Abstract

Entities:  

Mesh：

Year:  2000        PMID： 11106361      PMCID： PMC1734502          DOI： 10.1136/jmg.37.12.e43

Source DB:  PubMed          Journal:  J Med Genet        ISSN： 0022-2593            Impact factor:   6.318


× No keyword cloud information.
  4 in total

1.  Decreased bone mineral density and content in neurofibromatosis type 1: lowest local values are located in the load-carrying parts of the body.

Authors:  T Kuorilehto; M Pöyhönen; R Bloigu; J Heikkinen; K Väänänen; Juha Peltonen
Journal:  Osteoporos Int       Date:  2004-11-16       Impact factor: 4.507

2.  Women with neurofibromatosis 1 are at a moderately increased risk of developing breast cancer and should be considered for early screening.

Authors:  S Sharif; A Moran; S M Huson; R Iddenden; A Shenton; E Howard; D G R Evans
Journal:  J Med Genet       Date:  2007-03-16       Impact factor: 6.318

Review 3.  Psychosis related to neurological conditions: pro and cons of the dis- / mis-connectivity models of schizophrenia.

Authors:  Jack R Foucher; David Luck
Journal:  Dialogues Clin Neurosci       Date:  2006       Impact factor: 5.986

4.  Natural history of NF1 c.2970_2972del p.(Met992del): confirmation of a low risk of complications in a longitudinal study.

Authors:  Claire Forde; Emma Burkitt-Wright; Peter D Turnpenny; Eric Haan; John Ealing; Sahar Mansour; Muriel Holder; Nayana Lahiri; Abhijit Dixit; Annie Procter; Laurence Pacot; Dominique Vidaud; Yline Capri; Marion Gerard; Hélène Dollfus; Elise Schaefer; Chloé Quelin; Sabine Sigaudy; Tiffany Busa; Gabriella Vera; Lena Damaj; Ludwine Messiaen; David A Stevenson; Peter Davies; Sheila Palmer-Smith; Alison Callaway; Pierre Wolkenstein; Eric Pasmant; Meena Upadhyaya
Journal:  Eur J Hum Genet       Date:  2021-12-13       Impact factor: 4.246
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.